Research ExplorerPublicationsPrinted peptide arrays identify prognostic TNC serumantibodi...

Printed peptide arrays identify prognostic TNC serumantibodies in glioblastoma patients

Standard

Printed peptide arrays identify prognostic TNC serumantibodies in glioblastoma patients. / Mock, Andreas; Warta, Rolf; Geisenberger, Christoph; Bischoff, Ralf; Schulte, Alexander; Lamszus, Katrin; Stadler, Volker; Felgenhauer, Thomas; Schichor, Christian; Schwartz, Christoph; Matschke, Jakob; Jungk, Christine; Ahmadi, Rezvan; Sahm, Felix; Capper, David; Glass, Rainer; Tonn, Jörg-Christian; Westphal, Manfred; von Deimling, Andreas; Unterberg, Andreas; Bermejo, Justo Lorenzo; Herold-Mende, Christel.

In: ONCOTARGET, Vol. 6, No. 15, 12.04.2015, p. 13576-13590.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Mock, A, Warta, R, Geisenberger, C, Bischoff, R, Schulte, A, Lamszus, K, Stadler, V, Felgenhauer, T, Schichor, C, Schwartz, C, Matschke, J, Jungk, C, Ahmadi, R, Sahm, F, Capper, D, Glass, R, Tonn, J-C, Westphal, M, von Deimling, A, Unterberg, A, Bermejo, JL & Herold-Mende, C 2015, 'Printed peptide arrays identify prognostic TNC serumantibodies in glioblastoma patients', ONCOTARGET, vol. 6, no. 15, pp. 13576-13590. https://doi.org/10.18632/oncotarget.3791

APA

Mock, A., Warta, R., Geisenberger, C., Bischoff, R., Schulte, A., Lamszus, K., Stadler, V., Felgenhauer, T., Schichor, C., Schwartz, C., Matschke, J., Jungk, C., Ahmadi, R., Sahm, F., Capper, D., Glass, R., Tonn, J-C., Westphal, M., von Deimling, A., ... Herold-Mende, C. (2015). Printed peptide arrays identify prognostic TNC serumantibodies in glioblastoma patients. ONCOTARGET, 6(15), 13576-13590. https://doi.org/10.18632/oncotarget.3791

Vancouver

Mock A, Warta R, Geisenberger C, Bischoff R, Schulte A, Lamszus K et al. Printed peptide arrays identify prognostic TNC serumantibodies in glioblastoma patients. ONCOTARGET. 2015 Apr 12;6(15):13576-13590. https://doi.org/10.18632/oncotarget.3791

Bibtex

@article{77f5e0fbae48421188bb648a78cbe75c,
title = "Printed peptide arrays identify prognostic TNC serumantibodies in glioblastoma patients",
abstract = "Liquid biopsies come of age offering unexploited potential to monitor and react to tumor evolution. We developed a cost-effective assay to non-invasively determine the immune status of glioblastoma (GBM) patients. Employing newly developed printed peptide microarrays we assessed the B-cell response against tumor-associated antigens (TAAs) in 214 patients. Firstly, sera of long-term (36+ months, LTS, n=10) and short-term (6-10 months, STS, n=14) surviving patients were screened for prognostic antibodies against 1745 13-mer peptides covering known TAAs (TNC, EGFR, GLEA2, PHF3, FABP5, MAGEA3). Next, survival associations were investigated in two retrospective independent multicenter validation sets (n=61, n=129, all IDH1-wildtype). Reliability of measurements was tested using a second array technology (spotted arrays). LTS/STS screening analyses identified 106 differential antibody responses. Evaluating the Top30 peptides in validation set 1 revealed three prognostic peptides. Prediction of TNC peptide VCEDGFTGPDCAE was confirmed in a second set (p=0.043, HR=0.66 [0.44-0.t('bib99');return true;{"}>99]) and was unrelated to TNC protein expression. Median signals of printed arrays correlated with pre-synthesized spotted microarrays (p<0.0002, R=0.33). Multiple survival analysis revealed independence of age, gender, KPI and MGMT status. We present a novel peptide microarray immune assay that identified increased anti-TNC VCEDGFTGPDCAE serum antibody titer as a promising non-invasive biomarker for prolonged survival.",
author = "Andreas Mock and Rolf Warta and Christoph Geisenberger and Ralf Bischoff and Alexander Schulte and Katrin Lamszus and Volker Stadler and Thomas Felgenhauer and Christian Schichor and Christoph Schwartz and Jakob Matschke and Christine Jungk and Rezvan Ahmadi and Felix Sahm and David Capper and Rainer Glass and J{\"o}rg-Christian Tonn and Manfred Westphal and {von Deimling}, Andreas and Andreas Unterberg and Bermejo, {Justo Lorenzo} and Christel Herold-Mende",
year = "2015",
month = apr,
day = "12",
doi = "10.18632/oncotarget.3791",
language = "English",
volume = "6",
pages = "13576--13590",
journal = "ONCOTARGET",
issn = "1949-2553",
publisher = "IMPACT JOURNALS LLC",
number = "15",

}

RIS

TY - JOUR

T1 - Printed peptide arrays identify prognostic TNC serumantibodies in glioblastoma patients

AU - Mock, Andreas

AU - Warta, Rolf

AU - Geisenberger, Christoph

AU - Bischoff, Ralf

AU - Schulte, Alexander

AU - Lamszus, Katrin

AU - Stadler, Volker

AU - Felgenhauer, Thomas

AU - Schichor, Christian

AU - Schwartz, Christoph

AU - Matschke, Jakob

AU - Jungk, Christine

AU - Ahmadi, Rezvan

AU - Sahm, Felix

AU - Capper, David

AU - Glass, Rainer

AU - Tonn, Jörg-Christian

AU - Westphal, Manfred

AU - von Deimling, Andreas

AU - Unterberg, Andreas

AU - Bermejo, Justo Lorenzo

AU - Herold-Mende, Christel

PY - 2015/4/12

Y1 - 2015/4/12

N2 - Liquid biopsies come of age offering unexploited potential to monitor and react to tumor evolution. We developed a cost-effective assay to non-invasively determine the immune status of glioblastoma (GBM) patients. Employing newly developed printed peptide microarrays we assessed the B-cell response against tumor-associated antigens (TAAs) in 214 patients. Firstly, sera of long-term (36+ months, LTS, n=10) and short-term (6-10 months, STS, n=14) surviving patients were screened for prognostic antibodies against 1745 13-mer peptides covering known TAAs (TNC, EGFR, GLEA2, PHF3, FABP5, MAGEA3). Next, survival associations were investigated in two retrospective independent multicenter validation sets (n=61, n=129, all IDH1-wildtype). Reliability of measurements was tested using a second array technology (spotted arrays). LTS/STS screening analyses identified 106 differential antibody responses. Evaluating the Top30 peptides in validation set 1 revealed three prognostic peptides. Prediction of TNC peptide VCEDGFTGPDCAE was confirmed in a second set (p=0.043, HR=0.66 [0.44-0.t('bib99');return true;">99]) and was unrelated to TNC protein expression. Median signals of printed arrays correlated with pre-synthesized spotted microarrays (p<0.0002, R=0.33). Multiple survival analysis revealed independence of age, gender, KPI and MGMT status. We present a novel peptide microarray immune assay that identified increased anti-TNC VCEDGFTGPDCAE serum antibody titer as a promising non-invasive biomarker for prolonged survival.

AB - Liquid biopsies come of age offering unexploited potential to monitor and react to tumor evolution. We developed a cost-effective assay to non-invasively determine the immune status of glioblastoma (GBM) patients. Employing newly developed printed peptide microarrays we assessed the B-cell response against tumor-associated antigens (TAAs) in 214 patients. Firstly, sera of long-term (36+ months, LTS, n=10) and short-term (6-10 months, STS, n=14) surviving patients were screened for prognostic antibodies against 1745 13-mer peptides covering known TAAs (TNC, EGFR, GLEA2, PHF3, FABP5, MAGEA3). Next, survival associations were investigated in two retrospective independent multicenter validation sets (n=61, n=129, all IDH1-wildtype). Reliability of measurements was tested using a second array technology (spotted arrays). LTS/STS screening analyses identified 106 differential antibody responses. Evaluating the Top30 peptides in validation set 1 revealed three prognostic peptides. Prediction of TNC peptide VCEDGFTGPDCAE was confirmed in a second set (p=0.043, HR=0.66 [0.44-0.t('bib99');return true;">99]) and was unrelated to TNC protein expression. Median signals of printed arrays correlated with pre-synthesized spotted microarrays (p<0.0002, R=0.33). Multiple survival analysis revealed independence of age, gender, KPI and MGMT status. We present a novel peptide microarray immune assay that identified increased anti-TNC VCEDGFTGPDCAE serum antibody titer as a promising non-invasive biomarker for prolonged survival.

U2 - 10.18632/oncotarget.3791

DO - 10.18632/oncotarget.3791

M3 - SCORING: Journal article

C2 - 25944688

VL - 6

SP - 13576

EP - 13590

JO - ONCOTARGET

JF - ONCOTARGET

SN - 1949-2553

IS - 15

ER -